<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02712892</url>
  </required_header>
  <id_info>
    <org_study_id>RC15_0304</org_study_id>
    <nct_id>NCT02712892</nct_id>
  </id_info>
  <brief_title>I-CAN Biocollection</brief_title>
  <acronym>I-CAN</acronym>
  <official_title>IntraCranial ANeurysms: From Familial Forms to Pathophysiological Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nantes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nantes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intracranial aneurysm (IA) is an asymptomatic cerebrovascular abnormality affecting 3.2% of&#xD;
      the general population. The devastating complication of IA is its rupture, resulting in&#xD;
      subarachnoid haemorrhage that can lead to severe disability and death. Unfortunately, there&#xD;
      are neither reliable clues nor diagnostic tools to predict the formation and/or the fate of&#xD;
      an IA in a given individual. Also, there is no pharmacological drug available to prevent the&#xD;
      rupture of aneurysm and subsequent subarachnoid haemorrhage. Current treatments are invasive&#xD;
      with a significant risk of procedural morbidity. Thus, still now, the management of patients&#xD;
      with IA remains extremely challenging and still controversial. Although the pathogenesis of&#xD;
      IA has been the subject of many studies for the last decade, the mechanisms underlying IA&#xD;
      formation, growth and rupture are still mostly unknown and relevant animal models of IA are&#xD;
      not available. Familial history of IA predisposes to IA formation and rupture and increasing&#xD;
      evidence suggest a genetic component of IA formation, with heterogeneous modes of inheritance&#xD;
      and penetrance. This project, gathering neuroradiologists, geneticists and vascular&#xD;
      biologists, addresses the urgent need to understand the pathogenic mechanisms of IA to&#xD;
      develop diagnostic and predictive tools of risk of IA. The investigators propose to identify&#xD;
      IA-causing variants by whole-exome sequencing in familial forms of the disease. The&#xD;
      investigators hypothesises that the functional analysis of the causal/susceptibility variants&#xD;
      thus identified will provide clues to understanding the pathological mechanisms of IA&#xD;
      formation, and the bases for developing diagnostic tools. This project aims at meeting this&#xD;
      challenge. Based on preliminary data that already allowed to identify such a variant, and the&#xD;
      combination of genetic and functional investigations, the specific objectives of this project&#xD;
      are: - To identify IA-causing variants in familial forms of the disease by whole-exome&#xD;
      sequencing; - To understand the function of these genes/variants in the formation and rupture&#xD;
      of IA by molecular and cellular approaches and generation of relevant animal models; - To&#xD;
      discover potential biomarkers of risk of IA formation and/or rupture.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 3, 2016</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 19, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence or absence of genetic abnormalitie</measure>
    <time_frame>Until one year</time_frame>
    <description>Identification of genetic abnormalities segregant with the presence of intracranial aneurysms in the informative families recruited. Sequencing of the whole exome in a cohort of patients carriers of familial forms of intracranial aneurysms.&#xD;
Analysis of blood level of the GAIA 1 protein in a large cohort of familial and sporadic carriers of intracranial aneurysms</description>
  </primary_outcome>
  <enrollment type="Actual">3078</enrollment>
  <condition>Intracranial Aneurysm</condition>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Non Interventional Study</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      For one patient included:&#xD;
&#xD;
        -  2 Ethylenediaminetetraacetic acid (EDTA) tubes for DNA (5mL)&#xD;
&#xD;
        -  2 dry tubes for serum (5mL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The initial stage of this biocollection based on the recruitment of large families for&#xD;
        genetic linkage analysis. This is a first step to identify patients with intracranial&#xD;
        aneurysms occurring in a family context, and to conduct a comprehensive investigation&#xD;
        according to clinical guidelines in force to assess the potentially informative family and&#xD;
        ensure their adherence to the prior biocollection. The next step is the fine and accurate&#xD;
        phenotyping of each of the family members (imaging) and the collection of a blood sample&#xD;
        for DNA extraction for molecular genetic analysis.&#xD;
&#xD;
        The population recruited will be composed of index and their healthy relatives and cases&#xD;
        with sporadic cases and IA. The kinship links will be established from family trees.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria indexes and related cases (familial) of intracranial aneurysms:&#xD;
&#xD;
          -  Index: Any patient consulting for a major IA and some typical bifurcation with at&#xD;
             least one other case reached akin IA 1st degree&#xD;
&#xD;
          -  Related: All similar to the first degree, aged 20 or more, patients with a family&#xD;
             background of IA and some typical bifurcation (≥2 achieved) For the latter, directed&#xD;
             by screening with Magnetic resonance imaging (MRI) sequence Time of Flight (TOF),&#xD;
             axial T2, EGT2.&#xD;
&#xD;
          -  biocollection of Written Consent for participation in the collection of biological&#xD;
             samples&#xD;
&#xD;
        Inclusion criteria sporadic cases of IA:&#xD;
&#xD;
          -  Any patient consulting for IA and some typical bifurcation&#xD;
&#xD;
          -  Patients aged 20 years or older&#xD;
&#xD;
          -  biocollection of Written Consent for participation in the collection of biological&#xD;
             samples&#xD;
&#xD;
        Non Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have shown the inability or refusal to sign the consent informed&#xD;
             biocollection&#xD;
&#xD;
          -  syndromic diagnosis known as AIC provider&#xD;
&#xD;
               -  Marfan Syndrome&#xD;
&#xD;
               -  AOS with SMAD 3&#xD;
&#xD;
               -  Danlos Syndrome Elhers type II and IV&#xD;
&#xD;
               -  Autosomal Dominant Polycystic&#xD;
&#xD;
               -  Moyamoya Syndrome&#xD;
&#xD;
          -  character of IA:&#xD;
&#xD;
               -  Dissecting or fusiform&#xD;
&#xD;
               -  Combined with an arteriovenous malformation&#xD;
&#xD;
               -  Blister-like&#xD;
&#xD;
               -  mycotic&#xD;
&#xD;
          -  Pathology of the cerebral white matter detected on MRI suggestive:&#xD;
&#xD;
               -  Mutation COL4A1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hubert DESAL, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nantes University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Angers University Hospital</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Besançon University Hospital</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bordeaux University Hospital</name>
      <address>
        <city>Bordeaux</city>
        <zip>33404</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henri Mondor Hospital (AP-HP)</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dijon University Hospital</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Reunion University Hospital</name>
      <address>
        <city>La réunion</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kremlin-Bicêtre University Hospital (AP-HP)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Limoges University Hospital</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nancy University Hospital</name>
      <address>
        <city>Nancy</city>
        <zip>54035</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes University Hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lariboisière University Hospital (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Pitié-Salpétrière University Hospital (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sainte Anne Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rotschild Fundation</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poitiers University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes University Hospital</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toulouse University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours University Hospital</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 23, 2016</study_first_submitted>
  <study_first_submitted_qc>March 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2016</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Aneurysm</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

